18 completed, 9 not yet recruiting, 8 recruiting, 4 active not recruiting. 13 Phase 2, 11 Phase 1, 11 Phase 3, 5 Phase 4, 4 Not applicable.
Follow mazdutide: new trials by email Literature Review of mazdutide trials Research Report on mazdutide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Mazdutide on Fatty Pancreas mazdutide, Placebo matching mazdutide - Fatty Pancreas, Overweight | Not applicable | Not yet recruiting | Tongji Hospital | 194 | 2026-11-15 | 2026-09-22 |
| Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer Mazdutide(Dual GLP-1R/GCGR Agonist), Placebo, Levonorgestrel-releasing intrauterine system - Obesity, Overweight | Phase 2 | Not yet recruiting | Tongji Hospital | 128 | 2026-11-01 | 2026-08-24 |
| A Study of HRS-4729 Injection in Participants With Type 2 Diabetes HRS-4729 Injection, Mazdutide, Placebo - Type 2 Diabetes | Phase 2 | Not yet recruiting | Fujian Shengdi Pharmaceutical Co., Ltd. | 240 | 2026-10-01 | 2026-09-28 |
| Mazdutide for Remission of Type 2 Diabetes: Multicentre, Double Blind, Randomised, Placebo Controlled Trial Mazdutide, Placebo - Diabetes Mellitus, Type 2 | Not applicable | Not yet recruiting | Yanbing Li | 249 | 2026-09-30 | 2026-08-17 |
| Mazdutide for Weight Management and Gout in Adults With Obesity Mazdutide - Gout, Obesity (BMI>30) | Phase 4 | Not yet recruiting | Hongwei Jiang | 30 | 2026-09-15 | 2026-09-17 |
| Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity Mazdutide, Placebo - Obesity & Overweight, Coronary Heart Disease | Phase 4 | Recruiting | China National Center for Cardiovascular Diseases | 116 | 2026-09-14 | 2026-10-13 |
| Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME) Mazdutide, Placebo (Normal Saline), Lifestyle Optimization - Metabolic Dysfunction-Associated Steatohepatitis, Hepatic Steatosis | Phase 4 | Recruiting | West China Hospital | 60 | 2026-09-01 | 2026-09-23 |
| QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic Nephropathy empagliflozin, Finerenone, Mazdutide - Type 2 Diabetic Kidney Disease | Phase 4 | Not yet recruiting | Huijie Zhang | 820 | 2026-09-01 | 2026-08-20 |
| Body-weight Reduction Effect on Portal Hypertension in Compensated Cirrhosis Mazdutide injection - Cirrhosis, Portal Hypertension | Not applicable | Not yet recruiting | The Second Affiliated Hospital of Chongqing Medical University | 50 | 2026-09-01 | 2026-09-01 |
| Mazdutide for Adults With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial (DREAM-PRE) Mazdutide, Placebo, Standardized Lifestyle Intervention - Prediabetes, Impaired Fasting Glucose | Phase 4 | Not yet recruiting | Shandong Provincial Hospital | 150 | 2026-07-01 | 2026-06-17 |
| ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight Management Mazdutide, Intensive Lifestyle Intervention, Mazdutide Placebo - Obesity, Weight Control | Not applicable | Recruiting | Shanghai Zhongshan Hospital | 420 | 2026-06-10 | 2026-10-22 |
| Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity IBI362, Placebo - Overweight, Obesity | Phase 3 | Recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 336 | 2026-04-23 | 2026-05-27 |
| A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor HDM1005 1, HDM1005 2, Mazdutide - Type 2 Diabetes | Phase 3 | Not yet recruiting | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 912 | 2026-03-27 | 2026-02-18 |
| A Study of IBI362 in Chinese Adolescents With Obesity or Overweight Placebo, IBI362 - Adolescents With Obesity or Overweight With Weight-Related Comorbidities | Phase 3 | Recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 180 | 2025-12-29 | 2026-01-08 |
| Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study) Mazdutide, Placebo - Dementia, Mild, Mild Cognitive Impairment | Phase 3 | Recruiting | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 420 | 2025-09-27 | 2026-09-02 |
| A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) Placebo, IBI362 - Metabolic Dysfunction-associated Steatohepatitis (MASH) | Phase 2 | Active not recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 181 | 2025-06-20 | 2026-10-20 |
| Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity Tirzepatide, Placebo, IBI362 - Obesity | Phase 1 / Phase 2 | Active not recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 98 | 2025-06-17 | 2025-12-15 |
| A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2 placebo, IBI362 - Sleep Apnea, Obstructive | Phase 3 | Recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 260 | 2025-06-12 | 2025-06-29 |
| A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD） IBI362, semaglutide - Overweight, Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) | Phase 3 | Active not recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 479 | 2025-05-09 | 2026-05-12 |
| A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity placebo, IBI362 - Obesity, Heart Failure With Preserved Ejection Fraction (HFPEF) | Phase 2 | Active not recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 141 | 2025-03-26 | 2026-09-22 |
Showing 20 of 40. Sign in to see all of them.
Obesity (15) · Diabetes Mellitus, Type 2 (10) · Overweight (9) · Weight Loss (3) · Alcoholism (1) · Cognitive Dysfunction (1) · Coronary Disease (1) · Dementia (1) · Endometrial Hyperplasia (1) · Endometrial Neoplasms (1) · Fatty Liver (1) · Fibrosis (1) · Glucose Intolerance (1) · Gout (1) · Hypertension, Portal (1)
Innovent Biologics (Suzhou) Co. Ltd. (19) · Eli Lilly and Company (7) · Shanghai Zhongshan Hospital (2) · Tongji Hospital (2) · China National Center for Cardiovascular Diseases (1) · Fujian Shengdi Pharmaceutical Co., Ltd. (1) · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (1) · Hongwei Jiang (1) · Huijie Zhang (1) · Shandong Provincial Hospital (1) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (1) · The Second Affiliated Hospital of Chongqing Medical University (1) · West China Hospital (1) · Yanbing Li (1)
China (31) · United States (4) · United Kingdom (2) · Argentina (1) · Germany (1)
Gang Chen, Principal Investigator (1) · Hongwei Jiang, MD (1) · Jiajun Zhao, MD, PhD (1) · Linong Ji (1) · Lixin Guo, M.D (1) · Xiao Wang (1) · Yan Bi, MD, PhD (1) · Yan Yang (1)
PMID 34430840, PMID 35750681, PMID 36247927, PMID 37943529, PMID 38092790, PMID 40421736, PMID 40832785, PMID 41407860, PMID 41875890, PMID 42251595, PMID 42628555
2018 (1)